The Brutal Reality Check
2024 hit us with some devastating numbers.
A Chinese cohort study published in NDT (Nephrology Dialysis Transplantation) tracked 2,141 IgA nephropathy patients from 2003 to 2023.
The results? Absolutely brutal.
Most patients progressed to end-stage renal disease.
Here’s what the data actually shows:
- At 10 years: Only 61% kidney survival rate across all patients
- At 15 years: Drops to 40% – less than half make it
- At 10 years with proteinuria over 1g: Just 33% kidney survival
- At 10 years with proteinuria 0.5-1g: 78% survival
Let that sink in.
Even when proteinuria drops to 0.5-1g – which doctors consider a “good response” – 22% of patients still don’t make it past 10 years.
The 15-year numbers? Even worse.
We’ve always suspected IgA nephropathy hits harder than other kidney diseases. We knew Asian patients fare worse than Western populations. But this level of severity? Nobody saw it coming.
The only groups with decent outcomes: Patients maintaining proteinuria below 0.3-0.5g (94% survival) and below 0.3g (97% survival).
Since humans first identified IgA nephropathy in 1969, this disease has repeatedly shattered our understanding.
That initial impression of “mild proteinuria with stable kidney function”? Dead wrong.
Every decade brings another statistical gut punch showing this disease is far more aggressive than we thought.
Guidelines Finally Catch Up
For 30 years, IgA nephropathy treatment followed a simple pattern: Pick one of two main drugs.
Option 1: ACE inhibitors or ARBs (like enalapril or losartan)
Option 2: Immunosuppressants (steroids, leflunomide, mycophenolate)
Mild disease? Use Option 1.
Severe disease? Use Option 2.
Moderate disease? Pick one and hope for the best.
That era just ended.
The Kidney Disease: Improving Global Outcomes (KDIGO) organization – the heavyweight champion of nephrology guidelines – just dropped their 2025 IgA Nephropathy/Vasculitis Guidelines.
KDIGO doesn’t rush updates. When they update after just 4 years, you know something major shifted.
The last few years brought game-changing developments in IgA nephropathy treatment. The new guidelines reflect this reality with one clear message:
Stop choosing. Use both.
What Changed: Dual-Track Treatment Explained
Track 1: Mild Disease Can Handle Stronger Treatment Now
Traditional systemic steroids (prednisone, methylprednisolone) carried nasty side effects.
15+ pills daily. The side effect profile kept doctors from using them in mild cases.
Enter targeted therapy: Budesonide enteric-coated capsules.
Fewer side effects. No proteinuria restrictions anymore – you can use it at any level.
The problem? Cost and availability.
Budesonide runs expensive and constantly goes out of stock in many regions.
The solution: The guidelines now recommend a practical alternative:
“Half-dose steroids + infection prevention”
- Methylprednisolone 0.4 mg/kg/day (or prednisone 0.5 mg/kg/day)
- Maximum 32 mg/day
- Plus pneumocystis prophylaxis
More work for healthcare teams, but the benefit-to-risk ratio checks out.
Still worried about steroids? Switch to leflunomide, Tripterygium wilfordii, or mycophenolate mofetil – gentler immunosuppressants with fewer side effects.
Track 2: Severe Disease Needs “Mild” Drugs Too
When proteinuria exceeds 2.5g, studies consistently show steroids reduce both proteinuria and kidney failure risk.
Once you get results and drop proteinuria to 0.3-0.5g, do you still need ACE inhibitors or ARBs?
Many doctors used to think: “Nah, proteinuria’s low now. The old textbooks said risk only kicks in above 1g.”
Wrong.
Recent research killed that assumption. Even after immunosuppressants handle the heavy lifting, the remaining “small amount” of proteinuria still threatens kidney function.
You need both drugs.
New Guideline Recommendation 1.4.4.1:
“Unless contraindicated, all IgA nephropathy patients should receive maximum tolerated doses of ACE inhibitors or ARBs.” (Grade 1 recommendation, Level B evidence)
Plus: Sparsentan and SGLT2 inhibitors made the recommendation list too.
But should you use everything together?
What About Combining Everything?
Sparsentan and ACE inhibitors/ARBs both target the renin-angiotensin system.
Don’t combine them. Pick one.
SGLT2 inhibitors raise an interesting question.
The hard evidence – randomized controlled trials like DAPA-CKD and EMPA-KIDNEY – didn’t require patients to use ACE inhibitors/ARBs. These trials enrolled mostly patients with reduced kidney function, not those with normal kidney function and just proteinuria.
So the new guidelines only recommend SGLT2 inhibitors for IgA patients with eGFR below 60.
Normal kidney function with high proteinuria? Not enough solid evidence yet. Guidelines stay silent.
KDIGO remains characteristically cautious: Better to say nothing than say something wrong. Silence doesn’t mean “don’t do it” – it means “we’ll update when we get harder proof.”
Notice what’s missing? Cyclophosphamide, cyclosporine, tacrolimus, azathioprine – drugs IgA patients have used for decades. KDIGO has never recommended them. Not once in 20+ years.
That’s how conservative KDIGO operates. Even more cautious than drug regulatory agencies, who regularly revise and reverse their warnings.
Your Action Plan: What Actually Works
Based on the new guidelines and recent research, here’s what you need to do:
For Patients with Proteinuria 0.5-1g:
Don’t get complacent just because you’re “doing better.”
This range still carries 22% risk of kidney failure within 10 years.
Action steps:
- Maximize your ACE inhibitor/ARB dose (work with your nephrologist to find your maximum tolerated dose)
- Consider adding targeted immunosuppression (budesonide or low-dose steroids with prophylaxis)
- If eGFR drops below 60, discuss adding SGLT2 inhibitors
- Target proteinuria below 0.3g – this is your real safety zone
For Patients with Proteinuria Above 1g:
You’re in the high-risk zone. Aggressive treatment isn’t optional.
Action steps:
- Start immunosuppression immediately (discuss budesonide vs. steroid options with your doctor)
- Add maximum tolerated ACE inhibitor/ARB dose
- Monitor closely – monthly labs for the first 3-6 months
- Don’t stop treatment when you hit 0.5g – keep pushing to 0.3g or below
For Patients with Proteinuria Below 0.5g:
You’re in the best prognostic group. But maintenance matters.
Action steps:
- Continue maximum tolerated ACE inhibitor/ARB indefinitely
- Regular monitoring every 3-6 months
- Don’t skip appointments – catching increases early makes all the difference
- If proteinuria starts creeping up, add immunosuppression before it crosses 0.5g
Managing Side Effects
Steroid concerns? Monitor blood sugar, blood pressure, bone density, and watch for infections. Prophylaxis against pneumocystis is non-negotiable.
ACE inhibitor causing cough? Switch to an ARB. Similar benefits, different side effect profile.
Insurance won’t cover budesonide? The half-dose steroid protocol works. It requires more monitoring but achieves similar outcomes at lower cost.
The Bottom Line
IgA nephropathy loves targeting young people.
If you don’t get proteinuria below 0.5g – ideally below 0.3g – your chances of avoiding dialysis long-term look grim.
We used to think getting proteinuria under 1g was good enough. We thought pushing to 0.5g or 0.3g was “nice to have” – icing on the cake.
We were wrong.
It’s not icing. It’s the cake.
Getting to those ultra-low proteinuria levels isn’t optional optimization. It’s essential survival strategy.
The good news? Our treatment arsenal keeps expanding. Targeted steroids, SGLT2 inhibitors, novel agents in the pipeline – we have more tools than ever.
The convergence of two forces drove this guideline update:
- Brutal disease reality
- Better treatment options
The new approach: Attack both the cause (pathogenic IgA1 immune complexes) and the effect (kidney structural damage) simultaneously.
Control the IgA. Control the kidney disease. Both matter.
The guidelines aim to push that 10-year kidney survival rate from 61% up to 94% across all patients.
That’s the goal.
Whether we achieve it depends on how quickly nephrologists adopt these recommendations and how aggressively patients pursue treatment.
No more settling for “good enough” proteinuria levels.
No more choosing between treatment options when you need both.
The data forced our hand. The guidelines finally caught up.
Now it’s on us to execute.
Key Takeaways for Patients
- Get aggressive early: Waiting until kidney function drops means you’ve already lost ground
- Target proteinuria below 0.3g: Anything higher carries unacceptable long-term risk
- Use combination therapy: Unless contraindicated, you probably need both immunosuppression and RAS blockade
- Don’t fear side effects more than kidney failure: Modern protocols minimize steroid side effects while maximizing benefits
- Stay on treatment: IgA nephropathy is a marathon, not a sprint. Consistency matters more than perfection
- Work with specialized care: General practitioners mean well, but IgA nephropathy requires nephrologist expertise
The fight against IgA nephropathy just got more intense.
But for the first time in decades, we’re fighting with weapons that might actually win.
发表回复